BIOPOLE, EPALINGES, V8
Financial Results, Press Release
Annual Report to Security Holders
ADC Therapeutics Enters Amendment to Material Definitive Agreement
Corporate Presentation January 2026
Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Other Events
Reports Third Quarter 2025 Financial Results and Provides Operational Update
Corporate Presentation October 2025
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload